Discovery and Development

Discovery and Development

Innovations in pharmaceutical Discovery and Development Including Bioinformatics, Proteomics, Nanotechnology, Formulation and Recipients, Extractables and Leachables

Five Factors Driving Cell and Gene Therapy Developers Towards GammaretrovirusFive Factors Driving Cell and Gene Therapy Developers Towards Gammaretrovirus
Five Factors Driving Cell and Gene Therapy Developers Towards Gammaretrovirus

What has led to the rising trend for Cell & Gene Therapy (CGT) developers to choose retroviral vectors over other potential vectors, and what are the many drivers behind this selection process?

Dec 14, 2022 Discovery and Development
Collaboration and Centralisation: The Key to Successful Drug DevelopmentCollaboration and Centralisation: The Key to Successful Drug Development
Collaboration and Centralisation: The Key to Successful Drug Development

IPT talks to Dr Fiona McLaughlin and Neil Bell of Avacta Therapeutics about the need for cohesion when researching and developing a new drug between life science companies, academia, and medical practitioners

Dec 14, 2022 Discovery and Development
The Pioneering Tech Speeding Up Drug DevelopmentThe Pioneering Tech Speeding Up Drug Development
The Pioneering Tech Speeding Up Drug Development

IPT talks to Johannes Stanta at Celerion about how improvements in molecular and cellular capabilities are aiding Good Laboratory Practice/Good Clinical Practice (GLP/GCP) standards

Dec 14, 2022 Discovery and Development
An Alternative Regulatory Pathway for Generic Orally Inhaled Drug ProductsAn Alternative Regulatory Pathway for Generic Orally Inhaled Drug Products
An Alternative Regulatory Pathway for Generic Orally Inhaled Drug Products

The in vitro-in silico ‘alternative’ bioequivalence pathway for generic inhaled drug products, and how to factor in patient variability to successfully replace your comparative clinical end-point study

Dec 14, 2022 Discovery and Development
People, Pipelines, and Projections: Helping Emerging Therapeutics Get to Market EfficientlyPeople, Pipelines, and Projections: Helping Emerging Therapeutics Get to Market Efficiently
People, Pipelines, and Projections: Helping Emerging Therapeutics Get to Market Efficiently

From tools and assays, to the need for improved collaboration, the potential answers to this question are numerous. IPT asked representatives from DeciBio, Cybin, and GORE PharmBIO for their opinions

Oct 9, 2022 Discovery and Development
How API Manufacturers and Technology Suppliers Can Mitigate Potent API Processing RisksHow API Manufacturers and Technology Suppliers Can Mitigate Potent API Processing Risks
How API Manufacturers and Technology Suppliers Can Mitigate Potent API Processing Risks

Michael Avraam at ChargePoint Technology walks IPT through the challenges and obstacles that companies face when looking to build safety, quality, and efficiency into their potent active pharmaceutical ingredient (API) processes

Mar 31, 2022 Manufacturing
Improving Systems Integration in ManufacturingImproving Systems Integration in Manufacturing
Improving Systems Integration in Manufacturing

Pharma has been slow to adopt new technology in its manufacturing plants, partly because it fears change and partly because it often has a mix of legacy equipment. However, embracing greater interoperability through technology can smooth processes and support data integrity.

Mar 31, 2022 Manufacturing